Want to see SE:GUARD full AI Analyst Report?
GUARD Stock Chart & Stats
kr1.50
-kr0.02(-1.33%)
At close: 4:00 PM EDT
kr1.50
-kr0.02(-1.33%)
Day’s Range― - ―
52-Week Rangekr0.88 - kr27.00
Previous CloseN/A
Volume8.10K
Average Volume (3M)44.15K
Market Cap
kr61.80M
Enterprise Value-kr11.35
Total Cash (Recent Filing)kr40.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.07
Shares Outstanding44,588,066
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving zero reported debt is a durable financial strength for a clinical-stage biotech. It reduces near-term insolvency risk, preserves capacity to raise non-debt funding, and gives management flexibility to pursue R&D or partnerships without mandatory interest or principal repayment pressures.
Focused Therapeutic NicheA clear, specialized focus on acute kidney injury creates a defined clinical and regulatory pathway and may concentrate R&D expertise and IP. This niche positioning supports longer-term partnership and licensing opportunities with larger pharma seeking targeted nephrology assets.
Improving Net Loss TrendA materially smaller TTM loss versus the prior year signals improving expense control or lower cash burn. Sustained reduction in losses can extend runway, reduce near-term financing needs, and indicate management discipline—benefits that persist beyond short-term market moves.
Bears Say
No Revenue Or Commercial ProductsAs a clinical-stage company with no reported revenue, the business lacks internal cash generation and is entirely dependent on external financing or milestone/licensing events. This structural gap leaves long-term viability contingent on successful clinical progress and deals.
Persistent Cash BurnLarge, sustained negative operating and free cash flows are a durable liability for an R&D-stage biotech. Ongoing cash burn necessitates repeated external funding, increasing dilution risk and pressuring strategic options until a financing-independent commercial model is established.
Eroding Equity And Negative ROEA materially reduced equity base and negative ROE reflect accumulated losses and past dilution, weakening the balance sheet's shock-absorption capacity. This structural deterioration raises long-term financing risk and may constrain strategic flexibility absent material clinical or partnership milestones.
GUARD FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr0.88 and its highest was kr27.00 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr61.80M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Aug 20, 2026 which is in 9 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on May 11, 2026. The company reported -kr0.315 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 44,588,066 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -kr0.315 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:GUARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―